Axonics, Inc.
26 Technology Drive
Irvine, CA 92618
United States
949 396 6322
https://www.axonics.com
版塊: Healthcare
行業: Medical Devices
全職員工: 797
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Raymond W. Cohen | CEO & Director | 1.71M | 無 | 1959 |
| Mr. Rinda K. Sama | Chief Operating Officer | 902.83k | 1.78M | 1979 |
| Dr. John Woock Ph.D. | Executive VP, Chief Marketing & Strategy Officer | 902.83k | 1.06M | 1983 |
| Mr. Alfred J. Ford Jr. | Chief Commercial Officer | 902.96k | 無 | 1971 |
| Ms. Kari Keese | Chief Financial Officer | 無 | 無 | 無 |
| Mr. Guangqiang Jiang Ph.D. | Chief Technology Officer | 無 | 無 | 1974 |
| Mr. Neil Bhalodkar | Vice President of Investor Relations | 無 | 無 | 無 |
| Mr. Aaron Pettit | General Counsel & Chief Compliance Officer | 無 | 無 | 無 |
| Mr. Michael V. Williamson Esq., J.D. | Senior VP, General & IP Counsel | 無 | 無 | 1972 |
| Dr. Karen L. Noblett M.A.S., M.D. | Chief Medical Officer | 651.4k | 897.47k | 1963 |
描述
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
公司管治
截至 2024年4月1日 止，Axonics, Inc. 的 ISS 管治質素評分為 5。 Pillar 分數正在審核中：10；董事會：2；股東權利：4；現金賠償：2。
